Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a multicenter，randomized, double-blind, active-controlled, parallel-group study
comparing efficacy and safety of LY01011 (recombinant anti-RANKL human monoclonal antibody
injection) and Xgeva® in patients with bone metastases from solid tumors.